Kettner M, Krćméry V
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Drugs Exp Clin Res. 1988;14(8):511-7.
Widespread use of gentamicin in Czechoslovakia began in 1975 when it became more available, although its use remained restricted until 1986. Starting in 1980 a remarkable increase in gentamicin resistance was observed in Pseudomonas aeruginosa, Klebsiella, Enterobacter and several Proteus species, especially Proteus rettgeri. A large proportion of gentamicin-resistant strains came from the urine of hospitalized patients. In spite of infection control measures and restrictive antibiotic policy, gentamicin resistance has increased over the last years. In 1985 gentamicin resistance of bacteria in Czechoslovakia represented 18.2% and was higher than in Austria or the Federal Republic of Germany, for example, but lower than in Hungary, France, Greece and Italy. The usage of gentamicin has also increased. During the years 1982-1987 gentamicin usage in Czechoslovakia increased by one-half. In a representative collection of 69 gentamicin-resistant Gram-negative strains from seven regions of Czechoslovakia, the mechanisms of resistance to gentamicin, netilmicin, tobramycin and amikacin were studied. Production of acetyltransferases (AAC) and adenylyltransferases (ANT) was observed in 84% of strains. The majority of isolates produced AAC(3) enzymes (55%); production of ANT(2") represented the second most observed resistance mechanism (35%); only 14% of isolates produced AAC(6'). This resistance pattern correlates with patterns reported recently for Central and Southern Europe. Due to dissemination of plasmids coding for the AAC(3)-II enzyme, the majority of Czechoslovak gentamicin-resistant Gram-negative strains were also tobramycin- (87%) and netilmicin-resistant (68%). Amikacin remains the most effective aminoglycoside against multiresistant bacterial strains.
庆大霉素于1975年在捷克斯洛伐克开始广泛使用,当时其供应更加充足,不过直到1986年其使用仍受到限制。从1980年起,在铜绿假单胞菌、克雷伯菌属、肠杆菌属以及几种变形杆菌,尤其是雷氏变形杆菌中,观察到庆大霉素耐药性显著增加。很大一部分庆大霉素耐药菌株来自住院患者的尿液。尽管采取了感染控制措施和限制性抗生素政策,但在过去几年中庆大霉素耐药性仍有所增加。1985年,捷克斯洛伐克细菌的庆大霉素耐药率为18.2%,高于奥地利或德意志联邦共和国等国,但低于匈牙利、法国、希腊和意大利。庆大霉素的使用量也有所增加。在1982 - 1987年期间,捷克斯洛伐克的庆大霉素使用量增加了一半。在从捷克斯洛伐克七个地区收集的69株庆大霉素耐药革兰氏阴性菌株的代表性样本中,研究了对庆大霉素、奈替米星、妥布霉素和阿米卡星的耐药机制。在84%的菌株中观察到乙酰转移酶(AAC)和腺苷酸转移酶(ANT)的产生。大多数分离株产生AAC(3)酶(55%);ANT(2")的产生是第二常见的耐药机制(35%);只有14%的分离株产生AAC(6')。这种耐药模式与最近在中欧和南欧报道的模式相关。由于编码AAC(3)-II酶的质粒传播,大多数捷克斯洛伐克庆大霉素耐药革兰氏阴性菌株也对妥布霉素耐药(87%)和对奈替米星耐药(68%)。阿米卡星仍然是对抗多重耐药菌株最有效的氨基糖苷类药物。